Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib, Chidamide, and Fulvestrant in HR+ Metastatic Breast Cancer
NCT05186545Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jul 2022
- Primary completion
- Jan 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in breast cancer, sponsored by The First Affiliated Hospital of Zhengzhou University. Status: unknown.
02
Drugs
surufatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05186545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05186545.